Filing Details

Accession Number:
0001209191-18-048785
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-29 16:02:35
Reporting Period:
2018-08-27
Accepted Time:
2018-08-29 16:02:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1337553 Aerie Pharmaceuticals Inc AERI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1216984 A Thomas Mitro C/O Aerie Pharmaceuticals, Inc.
4301 Emperor Blvd., Suite 400
Durham NC 27703
President And Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-08-27 182,668 $3.15 234,147 No 4 M Direct
Common Stock Acquisiton 2018-08-27 7,332 $3.15 241,479 No 4 M Direct
Common Stock Disposition 2018-08-27 189,549 $60.27 51,930 No 4 S Direct
Common Stock Disposition 2018-08-27 451 $61.01 51,479 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (Right to Buy) Disposition 2018-08-27 182,668 $0.00 182,668 $3.15
Common Stock Option (Right to Buy) Disposition 2018-08-27 7,332 $0.00 7,332 $3.15
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
126,984 2017-08-05 2023-08-26 No 4 M Direct
63,498 2017-08-05 2023-09-12 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $60.00 to $60.95, inclusive.
  2. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 3 to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.00 to $61.05, inclusive.